Biogen (BIIB) PT Raised to $300 at Wedbush, After FDA Approves Aduhelm (Aducanumab)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Nasdaq falls as Alphabet set for record loss amid AI spending woes
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 250.80 +6.75 (2.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $244.05 | 52 Week High | $333.65 | |||
| Open | $250.15 | 52 Week Low | $223.02 | |||
| Day High | $255.55 | P/E | 32.11 | |||
| Day Low | $246.48 | EPS | $7.81 | |||
| Volume | 428,013 | |||||
